Business context and reporting period
DBV Technologies S.A. is a French clinical-stage biopharmaceutical company developing Viaskin epicutaneous immunotherapy, principally for food allergies. This is its audited annual report on Form 20-F for the fiscal year ended December 31, 2017—not a standalone Q4 report. Financial statements are prepared under IFRS as issued by the IASB and presented in euros.
The lead candidate, Viaskin Peanut, completed its Phase III program for children ages 4–11; Viaskin Milk remained in clinical development. The company had no approved therapeutic product and no product sales revenue in 2017.
Financial performance and position
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Operating income | €11.9m | €9.1m |
| Product sales revenue | €0 | €0 |
| Research and development expense | €105.2m | €78.8m |
| Sales and marketing expense | €15.8m | €11.3m |
| General and administrative expense | €35.8m | €35.0m |
| Operating loss | €145.0m | €116.0m |
| Financial profit (loss) | (€2.7m) | €1.5m |
| Net loss | €147.7m | €114.5m |
| Operating cash flow | (€114.3m) | (€59.5m) |
| Investing cash flow | (€7.8m) | (€8.3m) |
| Cash and cash equivalents at year-end | €137.9m | €256.5m |
Operating income was primarily research tax credits (€9.3m), subsidies (€0.3m), and €2.3m of other operating income, including deferred collaboration revenue recognized under the Nestlé Health Science agreement. R&D, sales and marketing, and G&A together totaled €156.9m in 2017; operating margins are not meaningful given the absence of product sales and substantial development spending.
At December 31, 2017, total assets were €177.8m, shareholders’ equity €129.9m, and total liabilities €47.9m, including €35.9m of current liabilities. Financial debt and conditional advances totaled €4.15m (€2.33m current and €1.83m non-current); the company reported no bank loans. Operating lease obligations were €15.0m. The filing reports no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Net loss widened by €33.2m, while operating loss increased by €29.0m. R&D spending rose 33.5%, largely reflecting clinical-trial activity and program expansion.
- Operating cash use increased by €54.8m; cash and cash equivalents fell by €118.6m. Financing cash flow was only €0.3m in 2017, compared with €1.7m in 2016; the major recent equity financing was the 2015 offering.
- Financial results shifted from €1.5m profit to €2.7m loss, mainly due to unrealized foreign-exchange effects on U.S.-dollar-denominated intercompany advances.
- Operating income increased 31.1%, but remained largely dependent on French research tax credits and collaboration-related recognition rather than product sales.
Outlook, commentary, risks and unusual items
- Liquidity and going concern: Management said year-end cash was not projected to fund its current operating plan for the next 12 months and disclosed material uncertainty about the company’s ability to continue as a going concern. The auditor issued an unqualified opinion on the financial statements with an explanatory going-concern paragraph. Management expected to seek equity or debt financing or modify plans; additional equity could dilute shareholders.
- Development outlook: Management planned to submit a U.S. BLA for Viaskin Peanut in the second half of 2018 and an EU marketing application by year-end 2018 or Q1 2019. These were forward-looking plans, not approvals. The FDA’s February 2018 agreement that available data supported BLA submission did not assure approval or eliminate the possibility of additional trials.
- Key clinical qualification: In PEPITES, 35.3% of Viaskin Peanut-treated patients responded versus 13.6% on placebo (p=0.00001), but the primary endpoint did not meet the prespecified 15% lower confidence-bound criterion; the reported 95% confidence interval for the response-rate difference was 12.4%–29.8%. REALISE met its safety objective; one active-arm patient had moderate anaphylaxis considered probably treatment-related. In February 2018, preliminary MILES results identified the 300 μg dose as having the greatest observed activity in children (ITT p=0.042).
- Other items: The company recorded a provision following a French tax reassessment of approximately €0.9m related primarily to research tax credits; management considered the prospects for relief very low. It reported a €9.2m receivable for the 2017 research tax credit, expected to be reimbursed in 2018. An interrupted OSEO-supported project led to approximately €1.7m of conditional advances being classified as current, with repayment timing under discussion.
- Execution risks: The business depends heavily on Viaskin candidates, regulatory outcomes, continued financing, manufacturing scale-up and third parties. The filing notes a single supplier of active pharmaceutical ingredients, reliance on contract manufacturers, ongoing ES GEN4.0 quality-control testing, and the risk that manufacturing or supply constraints delay development or commercialization. Competition, reimbursement and pricing, safety, and intellectual-property risks are also significant.
Important facts for investors to verify
- Whether financing was secured on terms sufficient to support the operating plan and how actual cash runway compared with management’s estimate.
- The full PEPITES analysis, particularly the failed prespecified confidence-bound criterion, its regulatory interpretation, and any subsequent FDA requirements or filing outcome.
- Viaskin Peanut and Viaskin Milk follow-up trial results, including safety, efficacy, and the design and timing of further studies.
- Readiness and validation of commercial-scale manufacturing, supply arrangements with Sanofi and FAREVA, and any resulting capacity, quality, or cost constraints.
- Collection and eligibility of research tax credits, resolution and repayment schedule of conditional advances, and potential dilution from future funding and equity awards.
- The filing states total employee headcount was 244 in one section and 242 in the financial-statement notes; investors should verify the correct year-end figure.